Mercyhealth Javon Bea Hospital - Rockton — Rockford, Illinois

Mercyhealth Javon Bea Hospital - Rockton is a clinical research site located in Rockford, Illinois, United States 61103.

Crixeo Clinical Trials Trust Score: 89/100 (GOOD). This profile has not yet been claimed by the site owner.

Mercyhealth Javon Bea Hospital - Rockton has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8.

Sponsors: SWOG Cancer Research Network.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Rockford

Browse all research sites in Illinois · View every site in Rockford

Sponsor Feasibility Report

Trust Score: 89/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mercyhealth Javon Bea Hospital - Rockton?

Mercyhealth Javon Bea Hospital - Rockton has a Crixeo Trust Score of 89/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mercyhealth Javon Bea Hospital - Rockton conducted?

Mercyhealth Javon Bea Hospital - Rockton has 1 clinical trials on record, with 1 currently active. Their work covers Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8.

Is Mercyhealth Javon Bea Hospital - Rockton accredited by Crixeo Clinical Trials?

Mercyhealth Javon Bea Hospital - Rockton has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mercyhealth Javon Bea Hospital - Rockton?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.